

TOW

Certificate of Mailing [37 CFR 1.8(a)]

I hereby certify that this paper and the documents referred to as attached therein are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Denise Ortega

Name

Denise Ortega

Signature

August 29, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Matthias Ebert et al.

Serial No.: 10/575,300

Group Art Unit:

Filed : April 12, 2006

Examiner:

For : MN/CA IX and Cancer Prognosis

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR SECTIONS 1.56, 1.97 AND 1.98

MAIL STOP PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The accompanying PTO Form 1449 is submitted pursuant to 37 CFR Sections 1.56, 1.97 and 1.98, directing Applicants to submit literature and information that may be considered material to the examination of the claims of an application. Applicants respectfully submit that this Information Disclosure Statement (IDS) should be considered in accordance with 37 CFR 1.97(b)(3), as it is being submitted "[b]efore the mailing date of a first Office action on the merits . . . " for the subject application, and that therefore, no fee is required for its consideration. However, should any fees be determined to be necessary in

connection with this paper, Applicants respectfully request that any such fees be charged to Deposit Account No. 12-0615.


Applicants respectfully point out that the "filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in Section 1.56(b)" [37 CFR Section 1.97(h)]; and that an information disclosure statement filed in accordance with 37 CFR Section 1.97 "shall not be construed as a representation that a search has been made." [37 CFR Section 1.97(g)]

Further the identification of any document herein is not intended to be, and, Applicants respectfully submit, should not be construed as being, an admission that such a document, in fact, constitutes "prior art" within the meaning of the applicable laws, since, for example, a given document may have a later effective date than at first seems apparent, or the document may have an effective date which can be antedated. Applicants respectfully conclude on this point that the "prior art" status of any document is a matter to be resolved during prosecution.

Thus, Applicants respectfully conclude that the citation of references herein is not intended to be an admission that any of the references are considered to be material or to constitute prior art, or that any of the references, either alone or in combination with any other references, would be sufficient



to render any of the claims of the above-identified patent  
application unpatentable.

Respectfully submitted

A handwritten signature in cursive script, appearing to read "Leona L. Lauder".

Leona L. Lauder  
Attorney for Applicant  
Registration No. 30,863

Dated: 8/29/06

  <p style="text-align: center;"><b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)</p>				Docket Number (Optional) <b>MST-2390.1</b>		Application Number <b>10/575,300</b>		
Applicant(s) <b>Matthias Ebert et al.</b>								
Filing Date <b>April 12, 2006</b>						Group Art Unit		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5,387,676	02/07/95	Zavada et al.	536	23.5	10/21/92	
		5,989,838	11/23/99	Zavada et al.	435	7.23	06/07/95	
		6,004,535	12/21/99	Zavada et al.	424	9.34	11/07/94	
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 03/089659	10/30/03		C12Q 1	00		
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Ashida et al., "Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma," <u>J Cancer Res Clin Oncol</u> 128: 561-568 (2002)						
		Brewer et al., "A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN," <u>Gynecologic Oncology</u> 63: 337-344 (1996)						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>				
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>MST-2390.1</b>	Application Number <b>10/575,300</b>
		Applicant(s) <b>Matthias Ebert et al.</b>	
		Filing Date <b>April 12, 2006</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	Bui et al., "Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy," <u>Clin. Cancer Res.</u> , 9: 802-811 (2003)
	Chen et al., "Expression of CA9 at the invasion front of gastric cancers," <u>Gut</u> , 54(7): 920-927 (2005)
	Chia et al., "Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma," <u>J Clin Oncol</u> , 19: 3660-3668 (2001)
	Cho et al., "Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma," <u>Br J Cancer</u> , 85: 563-567 (2001)
	Chrastina et al., "Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma." <u>Int J Cancer</u> , 105(6): 873-881 (2003)
	Giatromanolaki et al. "Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer," <u>Cancer Res</u> , 61:7992-7998 (2001)
	Ivanov et al., "Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer." <u>Am J Path</u> , 158(3): 905-919 (2001)
	Juhasz et al., "Expression of carbonic anhydrase IX in human pancreatic cancer," <u>Aliment Pharmacol Ther</u> , 18: 837-846 (2003)
	Karhumaa et al., "Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts," <u>Mol Hum Reprod</u> , 7: 611-616 (2001)
	Kivela et al., "Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors." <u>Dig Dis Sci</u> , 46(10): 2179-2186 (2001)
	Kivela et al., "Expression of transmembrane carbonic anhydrase isozymes IX and XII in normal human pancreas and pancreatic tumours," <u>Histochem Cell Biol</u> , 114: 197-204 (2000)
	Koukourakis et al., "Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy," <u>Clin Cancer Res</u> , 7: 3399-3403 (2001)
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>MST-2390.1</b>	Application Number <b>10/575,300</b>
		Applicant(s) <b>Matthias Ebert et al.</b>	
		Filing Date <b>April 12, 2006</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	Leppilampi et al., "Carbonic anhydrase isozymes IX and XII in gastric tumors," <u>World J Gastroenterol</u> , <b>9</b> : 1398-1403 (2003)
	Liao et al. "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial neoplasia and cervical carcinoma," <u>Am J Pathol</u> , <b>145</b> : 598-609 (1994)
	Loncaster et al., "Carbonic anhydrase expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix," <u>Cancer Res</u> , <b>61</b> : 6394-6399 (2001)
	Moss et al., " Inward growth of colonic adenomatous polyps," <u>Gastroenterology</u> , <b>111</b> : 1425-1432 (1996)
	Nishimori et al., "Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes." <u>Ann N Y Acad Sci.</u> , <b>880</b> : 5-16 (1999)
	Ortova Gut et al., "Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9," <u>Gastroenterology</u> , <b>123</b> : 1889-1903 (2002)
	Parkkila and Parkkila, "Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal," <u>Scand J Gastroenterol.</u> , <b>31</b> : 305-317 (1996)
	Parkkila et al., "Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro," <u>Proc Natl Acad Sci (USA)</u> , <b>97</b> : 2220-2224 (2000)
	Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," <u>Oncogene</u> , <b>9</b> : 2877-2888 (1994)
	Pastorekova and Zavada, "Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy," <u>Cancer Therapy</u> , <b>2</b> : 245-262 (2004)
	Pastorekova et al., "A Novel Quasi-viral Agent, MaTu, Is a Two-Component System," <u>Virology</u> , <b>187</b> : 620-626 (1992)
	Pastorekova et al., "Carbonic Anhydrase IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts," <u>Gastroenterology</u> , <b>112</b> : 398-408 (1997)
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>MST-2390.1</b>	Application Number <b>10/575,300</b>
		Applicant(s) <b>Matthias Ebert et al.</b>	
		Filing Date <b>April 12, 2006</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	Potter and Harris, "Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer," <u>Br J Cancer</u> , 89: 2-7 (2003)
	Risio, M., "Cell proliferation in colorectal tumor progression: an immunohistochemical approach to intermediate biomarkers," <u>J. Cell Biochem</u> , 16G: 79-87 (1992)
	Saarnio et al., "Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation," <u>Am J Pathol</u> , 153: 279-285 (1998)
	Saarnio et al., "Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumors," <u>J Hepatol</u> , 35: 643-649 (2001)
	Swinson et al., "Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia is associated with a poor prognosis in non-small cell lung cancer," <u>J Clin Oncol</u> , 21: 473-482 (2003)
	Turner et al., "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker," <u>Human Pathol</u> , 28: 740-744 (1997)
	Uemura et al., "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas," <u>Br. J. Cancer</u> , 81:741-746 (1999)
	Wykoff et al. "Hypoxia-inducible expression of tumor-associated carbonic anhydrases," <u>Cancer Res</u> , 60: 7075-7083 (2000)
	Zavada et al., "Expression of MaTu-MN protein in human tumor cultures and in clinical specimens," <u>Int J Cancer</u> , 54: 268-274 (1993)
	Zhong et al., "Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases," <u>Cancer Res</u> , 59: 5830-5835 (1999)

EXAMINER	DATE CONSIDERED
----------	-----------------

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.